Can Sotorasib be used in patients with bowel cancer?

Sotorasib is a KRAS G12C mutation-specific inhibitor that is currently approved for the treatment of patients with non-small cell lung cancer (NSCLC) carrying this mutation. KRAS G12C mutations are also present in certain cancer types, such as colorectal cancer (colloquially known as "bowel cancer"), so researchers are beginning to explore sotorasib's therapeutic potential in these patients. However, compared with lung cancer, the efficacy of sotoracib in colorectal cancer is relatively limited and requires comprehensive evaluation.

Clinical trial data show that in patients with KRAS G12C mutated colorectal cancer, sotoraxib monotherapy has a low efficacy rate and a shorter median progression-free survival. This may be related to factors such as the complex tumor microenvironment of colorectal cancer, the large number of concomitant mutations, and the poor response to single targeted therapy. Therefore, sotoraxib is currently not officially approved for the treatment of colorectal cancer and is only used in clinical trials or special circumstances.

In order to improve the efficacy, researchers have tried to combine sotoracib with other drugs, such as EGFR inhibitors (such as cetuximab), which have shown better anti-tumor activity in some patients. This suggests that in selected patients, sotoraxib may be useful as part of a combination treatment, but more clinical studies are needed to verify efficacy and safety.

In short, sotoracib has certain application prospects in intestinal cancer, provided that the patient clearly has the KRAS G12C mutation and the applicability is evaluated under the guidance of a professional doctor. At present, this drug has not yet become part of the standard treatment for bowel cancer. If patients are willing to try it, they should give priority to participating in relevant clinical research projects.

Reference materials:https://www.lumakras.com/